Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocugen Inc
(NQ:
OCGN
)
1.850
-0.070 (-3.65%)
Streaming Delayed Price
Updated: 11:35 AM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocugen Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
April 11, 2023
Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis
From
Ocugen
Via
GlobeNewswire
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
March 31, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
March 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
March 07, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
March 06, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
February 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
February 17, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Appoints Quan A. Vu as Chief Business Officer
February 01, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
January 31, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
January 09, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
December 16, 2022
Important next step for Ocugen’s regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
December 13, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
December 07, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
November 28, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
November 08, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
October 27, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
October 19, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
October 12, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
October 06, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 29, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
September 28, 2022
From
Ocugen
Via
GlobeNewswire
MarketBeat: Week in Review 8/22 - 8/26
August 27, 2022
The markets are selling on news that interest rate hikes will continue past September. But here are some of the other stories for investors to follow this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Are Ocugen or Amarin Good Penny Stocks to Buy?
August 24, 2022
This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing.
Via
MarketBeat
OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN
October 08, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
Ocugen, Inc. (NASDAQ:OCGN) Long Term Investor Alert: Investigation of Potential Wrongdoing
September 28, 2021
San Diego, CA -- (SBWIRE) -- 09/28/2021 -- Certain directors of Ocugen, Inc are under investigation concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc.
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN
September 10, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
LAWSUITS FILED AGAINST OCGN, DKNG and PLL - Jakubowitz Law Pursues Shareholders Claims
August 17, 2021
NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
CLASS ACTION UPDATE for OCGN, HMPT and ARDX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
August 16, 2021
NEW YORK, NY / ACCESSWIRE / August 16, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....
From
Levi & Korsinsky, LLP
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.